As the inhibition of CIP2A may allow for the PP2A-mediated proteolytic degradation of c-Myc in cancer cells and thereby limit the cancer cells’ growth and transformation, the CIP2A may be a promising candidate for targeted treatment [18,19]. This evidence concerns the gene PTPA and cancer.